EUVIMEDEUVIMED entdecken
Crossref

[68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer

Yao Liu, Zhaohui Chu, Xiaoding Jin, Yanfei Wu, Donglang Jiang, You Zhang, Yue Gu, Qi Ge, Yuanyuan Chen, Xiwen Xu, Wei Zhang, Chengyu Chu und 4 weitere

European Journal of Nuclear Medicine and Molecular Imaging · 2026-06 · 53 (7) · 4597-4605

DOI: 10.1007/s00259-026-07796-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, online erschienen am 05.03.2026. Verfasst von Yao Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200040, China. Hauptthemen laut MEDLINE: Antigens, Neoplasm, Positron Emission Tomography Computed Tomography, Breast Neoplasms, Cell Adhesion Molecules. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: STI2030-Major Projects (2022ZD0213800).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Gallium-68([68Ga])-labeled Ga-NOTA-T4 PET/CT is a promising noninvasive imaging tool for visualizing trophoblast cell-surface antigen 2 (TROP2) expression, which could aid clinical decisions regarding TROP2-targeted therapies. This study aims to evaluate the diagnostic performance of [68Ga]Ga-NOTA-T4 PET/CT, a novel TROP2-targeting tracer, for detecting TROP2 expression in HER2-negative breast cancer. METHODS: From September 2023 to March 2025, we retrospectively reviewed patients with HER2-negative breast cancer at Huashan Hospital, Fudan University. All participants underwent [68Ga]Ga-NOTA-T4 PET/CT, with or without [18F]FDG PET/CT. RESULTS: A total of 42 patients were enrolled in the study, among whom 27 underwent both [68Ga]Ga-NOTA-T4 and [18F]FDG PET/CT imaging. [68Ga]Ga-NOTA-T4 PET/CT demonstrated comparable capability to [18F]FDG in identifying both patients and metastatic lesions. Among patients with Luminal B HER2-negative breast cancer, those who had received endocrine therapy or chemotherapy demonstrated significantly higher [⁶⁸Ga]Ga-NOTA-T4 uptake compared to untreated patients (SUVmax: 5.20 ± 5.07 vs. 3.36 ± 3.52; p = 0.008). A similar trend was observed in Luminal A patients, with higher SUVmax values in the treated group; however, the difference did not reach statistical significance (SUVmax: 8.35 ± 6.41 vs. 5.60 ± 4.55; p = 0.241). In TNBC patients, treatment was associated with significantly lower [⁶⁸Ga]Ga-NOTA-T4 uptake compared to those who were untreated (SUVmax: 3.02 ± 2.35 vs. 7.63 ± 5.64; p = 0.008). CONCLUSIONS: [68Ga]Ga-NOTA-T4 PET/CT is a promising tool for visualizing TROP2 expression in breast cancer, with potential applications for patient stratification and precision therapy. In Luminal B breast cancer, SUVmax increased with initial TROP2-targeted ADC therapy but decreased after multiple endocrine therapy or chemotherapy treatments. In TNBC, SUVmax decreased upon initial therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, NeoplasmPositron Emission Tomography Computed TomographyBreast NeoplasmsCell Adhesion MoleculesErb-b2 Receptor Tyrosine KinasesGene Expression Regulation, NeoplasticHeterocyclic Compounds, 1-RingHeterocyclic CompoundsHumansFemaleMiddle AgedAgedRetrospective StudiesGallium RadioisotopesAdult

Stichwörter der Autor:innen

Breast cancerMolecular imagingTROP2[68Ga]Ga-NOTA-T4.

Substanzen

Antigens, NeoplasmTACSTD2 protein, humanCell Adhesion MoleculesErb-b2 Receptor Tyrosine KinasesGallium RadioisotopesERBB2 protein, humanHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, 200040, China.
  • Department of Oncology, Huashan Hospital, Fudan University, Shanghai, 200040, China.
  • Department of Thyroid and Breast Surgery, General Surgery, Huashan Hospital, Fudan University, Shanghai, 200040, China.
  • Department of Nuclear Medicine, Institute of Clinical Nuclear Medicine, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200040, China.
  • Central Research Institute, United Imaging Healthcare Group Co,Ltd, Shanghai, 201807, China.
  • Department of Pathology, Huashan Hospital, Fudan University, Shanghai, 200040, China.

ORCID-Profile: Fang Xie

Förderung

  • STI2030-Major Projects (2022ZD0213800)

Zitieren

APA

Liu, Y., Chu, Z., Jin, X., Wu, Y., Jiang, D., Zhang, Y., Gu, Y., Ge, Q., Chen, Y., Xu, X., Zhang, W., Chu, C., Guan, Y., Wei, W., Jin, Y., & Xie, F. (2026). [68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging, 53(7), 4597-4605. https://doi.org/10.1007/s00259-026-07796-4

Vancouver

Liu Y, Chu Z, Jin X, Wu Y, Jiang D, Zhang Y, et al. [68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2026;53(7):4597-4605. doi:10.1007/s00259-026-07796-4

BibTeX
@article{Liu2026,
  author = {Liu, Yao and Chu, Zhaohui and Jin, Xiaoding and Wu, Yanfei and Jiang, Donglang and Zhang, You and Gu, Yue and Ge, Qi and Chen, Yuanyuan and Xu, Xiwen and Zhang, Wei and Chu, Chengyu and Guan, Yihui and Wei, Weijun and Jin, Yiting and Xie, Fang},
  title = {[68Ga]Ga-NOTA-T4 PET/CT imaging of TROP2 expression in patients with HER2-negative breast cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  volume = {53},
  number = {7},
  pages = {4597--4605},
  doi = {10.1007/s00259-026-07796-4}
}
Kostenlos starten →